



September 7, 2011

Galectin Therapeutics to Present Corporate Update at the Rodman & Renshaw Healthcare Conference

NEWTON, Mass., Sep 07, 2011 (BUSINESS WIRE) -- Galectin Therapeutics Inc. (OTC: GALT) today announced that Peter G. Traber, M.D., Chief Executive Officer, will present a corporate update at the Rodman & Renshaw Healthcare Conference on Tuesday, September 13th at the Waldorf-Astoria Hotel in New York City. Dr. Traber's presentation is scheduled to be webcast live at 3:40 pm EDT and can be accessed at: <http://www.wsw.com/webcast/rrshq20/galt>.

Galectin Therapeutics Portfolio Overview

Galectin Therapeutics is focusing its galectin inhibitor development efforts in two key disease areas: fibrosis and cancer.

- **Liver Fibrosis:** The Company is developing galectin inhibitors to treat liver fibrosis and the later stage of cirrhosis. Galectin Therapeutics candidates have demonstrated the ability to arrest and reverse liver fibrosis in pre-clinical studies.
- Approximately 47,000 deaths from cirrhosis occurred last year in the United States of which only 6,291 of the approximately 400,000 U. S. cirrhosis patients received life saving liver transplants. Liver fibrosis is a disease with no current treatment options except liver transplantation.

Galectin Therapeutics' efforts in cancer encompass two distinct programs, cancer immunotherapy and chemotherapy.

- **Cancer Immunotherapy:** Recent experiments by The Ludwig Institute of Cancer Research in Brussels, Belgium indicated that GM-CT-01 reactivates T-cell-dependent tumor cell killing that had been turned off by galectins secreted by cancer cells. The Ludwig Institute is planning a Phase 1/2 trial of GM-CT-01 for patients with advanced metastatic melanoma. Patients will receive a tumor-specific peptide vaccination combined with multiple systemic and intra-tumor doses of GM-CT-01 following the second month and subsequent month's vaccine administration.
- **Cancer Chemotherapy:** The Company is currently awaiting review of its application for marketing approval in Colombia, South America for the use of GM-CT-01 (formerly known as DAVANAT[®]) in combination with 5-FU for metastatic colorectal cancer. GM-CT-01 will be commercialized by Galectin Therapeutics' partner PROCAPS in Colombia, pending regulatory approval in that country.

About Galectin Therapeutics

Galectin Therapeutics (OTC: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at <http://www.galectintherapeutics.com>.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

SOURCE: Galectin Therapeutics Inc.

Galectin Therapeutics

Anthony D. Squeglia, 617-559-0033

Chief Financial Officer

squeglia@galectintherapeutics.com